Next 10 |
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...
2023-12-01 12:03:58 ET More on Navidea Biopharm Financial information for Navidea Biopharm For further details see: Navidea settles litigation with Capital Royalty, stock rallies 30%
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focuse...
The Company announced today that the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the NYSE American LLC upheld the NYSE Regulation staff’s previously announced determination to initiate delisting proceedings with respect to the Company’s com...
Following the Company’s Fix, Fund, Propel approach, Navidea formally submitted a request for an oral hearing with New York Stock Exchange American (NYSE American) Hearing Panel to appeal potential delisting of its stock from the NYSE American. Navidea Biopharmaceuticals, Inc. (NY...
2023-07-31 09:48:33 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips SoFi Technologies (NASDAQ: SOFI ) stock is on the rise Monday after the financial services company released results for the second quarter of 2023 . The good news for SO...
Following the Company’s Fix, Fund, Propel approach, Navidea continues forward-focus to advance innovative technology to market while intending to appeal the potential delisting of its stock from the New York Stock Exchange (NYSE). Navidea Biopharmaceuticals, Inc. (NYSE American: ...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC ("NYSE American" or the "Exchange...
2023-07-27 18:01:42 ET Navidea Biopharmaceuticals ( NYSE: NAVB ) on Thursday said it had named Craig Dais as its CFO. According to NAVB, Dais has over 30 years of executive experience. NAVB said Dais' hiring aligned with its "Fix, Fund, Propel approach to advancin...
Following the Company’s Fix, Fund, Propel approach, Mr. Dais’s hire strengthens financial expertise, leadership, and oversight, along with continuing Navidea’s focus on advancing innovative technology to market Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ...
News, Short Squeeze, Breakout and More Instantly...
Navidea Biopharmaceuticals Inc. Company Name:
NAVB Stock Symbol:
NYSE Market:
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focuse...
The Company announced today that the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the NYSE American LLC upheld the NYSE Regulation staff’s previously announced determination to initiate delisting proceedings with respect to the Company’s com...